Results 21 to 30 of about 6,232 (197)
Podocalyxin in Rat Platelets and Megakaryocytes [PDF]
The American Journal of Pathology, 1999 Podocalyxin is a membrane protein of rat podocytes and endothelial cells. It has not been described in other cell types, and no amino acid or DNA sequence data are available about it. Here we show that podocalyxin antigens are present in rat platelets and megakaryocytes.
A, Miettinen +5 more
openaire +2 more sources
Podocalyxin regulates murine lung vascular permeability by altering endothelial cell adhesion. [PDF]
PLoS ONE, 2014 Despite the widespread use of CD34-family sialomucins (CD34, podocalyxin and endoglycan) as vascular endothelial cell markers, there is remarkably little known of their vascular function.
Erin J Debruin +9 more
doaj +1 more source
Podocalyxin regulates pronephric glomerular development in zebrafish [PDF]
Physiological Reports, 2013 Vertebrate glomerular podocytes possess a highly sialylated transmembrane glycoprotein, Podocalyxin. In mammals, the sialic acid of Podocalyxin plays a crucial role in the formation of the characteristic podocyte architecture required for glomerular filtration. We examined the function of Podocalyxin in the developing zebrafish pronephros by disrupting
Ichimura, Koichiro +5 more
openaire +2 more sources
Urinary podocalyxin: Is it a real index of disease activity in egyptian patients lupus nephritis?
Saudi Journal of Kidney Diseases and Transplantation, 2020 Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by production of a number of antinuclear antibodies. Podocyte injury is an important feature and can be detected by several markers including podocalyxin.
Ahmed Fayed +5 more
doaj +1 more source
Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma. [PDF]
PLoS ONE, 2015 Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers with poor prognosis and unfavorable clinicopathological characteristics.
Kapo Saukkonen +8 more
doaj +1 more source
Advances in Biomarker Sciences and Technology, 2023 Background: Recombinant human erythropoietin (rHuEPO) is an effective treatment for renal anemia. Recently, there is evidence to suggest that rHuEPO may reduce podocyte injury in diabetic kidney disease (DKD).
Lingfeng Zeng +5 more
doaj +1 more source
Kidney Medicine, 2023 Rationale & Objective: Diabetic kidney diseases (DKDs) are the most common cause of dialysis-dependent kidney disease around the world. Previous studies have suggested that urinary level of podocyte-associated molecules may predict the prognosis of ...
Lingfeng Zeng +5 more
doaj +1 more source
Relationship between Elevated Maternal Serum Podocalyxin Concentrations with Blood Pressure Values and Routine Laboratory Parameters in Preeclampsia [PDF]
Journal of Biomedical & Clinical Research, 2021 Podocalyxin (PCX) is a glycoprotein member of the CD34 transmembrane sialomucin family and covers the surface of podocytes. It is assumed to be a marker of glomerular endothelial injury. In conditions, podocalyxin excretion in the urine is increased as a
Nikola Popovski +3 more
doaj +3 more sources
Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis [PDF]
, 2017 IgA nephropathy (IgAN) is the most prevalent among primary glomerular diseases worldwide. Although our understanding of IgAN has advanced significantly, its underlying biology and potential drug targets are still unexplored.
Cisek, Katryna +11 more
core +5 more sources
The Role of Podocalyxin in Health and Disease [PDF]
Journal of the American Society of Nephrology, 2009 Podocalyxin, a sialomucin most closely related to CD34 and endoglycan, is expressed by kidney podocytes, hematopoietic progenitors, vascular endothelia, and a subset of neurons; aberrant expression has recently been implicated in a range of cancers.
Julie S, Nielsen, Kelly M, McNagny
openaire +2 more sources